TLR4 and melanoma: AT-I had the anti-tumor effects against many cancers, such as colorectal cancer (Li et al., 2020), non-small cell lung cancer (Guo et al., 2019) and melanoma (Fu et al., 2018), and it also had a binding site similar to LPS and served as a novel TLR4-antagonizing agent (Liu et al., 2016).